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Abstract  
Polymersomes have the potential to encapsulate and deliver chemotherapeutic drugs into tumour 
cells, reducing off-target toxicity that often compromises anti-cancer treatment. Here we assess 
the ability of the pH-sensitive poly 2-(methacryloyloxy)ethyl phosphorylcholine (PMPC)- poly 
2-(diisopropylamino)ethyl methacrylate (PDPA) polymersomes to encapsulate chemotherapeutic 
agents for effective combinational anti-cancer therapy. Polymersome uptake and ability to 
deliver encapsulated drugs into healthy normal oral cells and oral head and neck squamous cell 
carcinoma (HNSCC) cells was measured in two and three-dimensional culture systems. PMPC-
PDPA polymersomes were more rapidly internalised by HNSCC cells compared to normal oral 
cells. Polymersome cellular up-take was found to be mediated by class B scavenger receptors. 
We also observed that these receptors are more highly expressed by cancer cells compared to 
normal oral cells, enabling polymersome-mediated targeting. Doxorubicin and paclitaxel were 
encapsulated into pH-sensitive PMPC-PDPA polymersomes with high efficiencies either in 
isolation or as a dual-load for both singular and combinational delivery. In monolayer culture, 
only a short exposure to drug-loaded polymersomes was required to elicit a strong cytotoxic 
effect. When delivered to three-dimensional tumour models, PMPC-PDPA polymersomes were 
able to penetrate deep into the centre of the spheroid resulting in extensive cell damage when 
loaded with both singular and dual-loaded chemotherapeutics. PMPC-PDPA polymersomes offer 
a novel system for the effective delivery of chemotherapeutics for the treatment of HNSCC. 
Moreover, the preferential internalisation of PMPC polymersomes by exploiting elevated 
scavenger receptor expression on cancer cells opens up the opportunity to target polymersomes 
to tumours. 
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Introduction 
Appropriate and effective delivery is vital to a drug’s therapeutic success.  In order for a drug to 
exert its therapeutic effect it must be delivered to the target cells, at the optimum dose and in its 
active form.  Drugs delivered inappropriately to healthy tissues and organs can produce off-target 
effects that may limit the dose that these drugs can be administered, resulting in sub-optimal or 
even abandoned treatment. Many anti-cancer drugs target cell proliferation by utilising the 
abnormal growth of cancerous cells. For example, doxorubicin acts by intercalating the DNA to 
inhibit cell division. Unfortunately, doxorubicin administration is associated with severe 
cardiotoxicity, limiting its use1.  Poor drug solubility is also a great challenge in drug 
development. The commonly used anti-cancer agent paclitaxel is a potent inhibitor of mitosis but 
is poorly soluble in water (aqueous solubility is around 0.6 mM)2. Paclitaxel is therefore 
administered in conjunction with the stabilizing agent Kolliphor EL (formally known as 
Cremophor EL) to ensure that therapeutically sufficient doses are delivered to the patient. 
However, Kolliphor EL has been associated with acute hypersensitivity reactions and systemic 
immunostimulation in some patients that limits its use3.  Long systemic circulation times and 
reduced clearance by the reticular endothelium system are also crucial if drugs are to be 
delivered to tissues at therapeutic concentrations.  
The last decade has seen a dramatic increase in research into the use of various nanoparticles to 
deliver therapeutic agents to overcome some of these challenges. Since the pioneering work of 
Maeda and co-workers4, it is now well established that the leaky vasculature associated with 
tumour growth favours the accumulation of macromolecules and nanocarriers in the tumour due 
the enhanced permeability and retention (EPR) effect4. This observation has lead to the 
development of several nanoparticles that act as carriers and passively target solid tumours. 
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Several of these have now reached the clinic including Doxil® (Caelyx®), a polyethylene glycol 
(PEG)-conjugated liposome formulation of doxorubicin that shows reduced cardiotoxicity 
compared to doxorubicin alone5. However, Doxil® therapy is not without its own side-effects as 
its use has resulted in hand-foot syndrome in some patients6. These adverse effects are mitigated 
by using non-PEGylated liposomal formulations such as Myocet®7. However, these agents have 
much shorter circulation half-life in the blood and consequently less accumulation in tumours. A 
number of liposomal formulations for paclitaxel drug delivery are currently in clinical trials8. 
One of the main limitations of liposomal preparations is their short half-life and their inherent 
slow release of their therapeutic cargo which has led us and others to develop other synthetic 
alternatives9,10. Synthetic polymers are showing great promise11 particularly in recent years 
where liposome and polymer technology have merged in the design of self-assembling 
membrane-enclosed structures comprised of block copolymers called polymersomes12,13,14. 
Polymersomes have been shown to exhibit longer half-lives and better tumour accumulation 
compared to PEGylated liposomes15. Advances in polymer synthesis techniques have enabled 
polymers to be designed with optimum properties for drug delivery including high molecular 
weights, enhanced stability, side chain functionality and more importantly, responsiveness 12-14, 
16.  
Cancers originating in the head and neck region and oral cavity are potentially more accessible to 
local chemotherapeutic drug delivery17 and could ultimately utilise the transmucosal delivery 
capability of these polymersomes seen in vitro18. Here we investigate the use of polymersomes 
comprised of the amphiphilic block copolymer poly 2-(methacryloyloxy)ethyl phosphorylcholine 
(PMPC) coupled with the pH-sensitive copolymer poly 2-(diisopropylamino)ethyl methacrylate 
(PDPA) for anti-cancer drug delivery. PMPC-PDPA polymersomes have been demonstrated to 
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be internalised via endocytosis19 and dissociate within the low pH in the endosomal 
compartment, releasing their cargo into the cell cytosol20. Indeed, polymersomes have been used 
to deliver DNA, siRNA, proteins and antibodies into live cells21, 22, 23, 24.  
The membrane-enclosed vesicular structure of polymersomes enables both hydrophilic and 
hydrophobic materials to be encapsulated within their aqueous core and the hydrophobic 
membrane respectively25. This is particularly important as combination therapies have been 
shown to improve response rates in head and neck squamous cell cancer (HNSCC)26. In this 
study, the internalization kinetics of PMPC-PDPA polymersomes into human HNSCC, normal 
oral cells and three-dimensional (3D) multi-cellular tumour spheroids (MCTS) were 
investigated. The ability of polymersomes to encapsulate chemotherapeutic drugs (paclitaxel and 
doxorubicin) and the effect of polymersome-mediated drug delivery were assessed both alone 
and in combination. Finally, uptake mechanisms were investigated to identify the target receptors 
involved in internalisation of polymersomes into cells. 
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Materials and Methods 
All reagents were purchased from Sigma-Aldrich (Poole, UK) unless stated otherwise and used 
as described by the manufacturer’s instructions. 
 
PMPC25-PDPA70 copolymer synthesis 
PMPC25-PDPA70 copolymer was synthesized by atom transfer radical polymerization (ATRP) as 
reported elsewhere27. Briefly, a Schlenk flask was charged with CuBr (25.6 mg, 0.178 mmol) 
and 2-Methacryloyloxyethyl phosphorylcholine (MPC) (1.32 g, 4.46 mmol; Biocompatibles 
Ltd). 2-bromo-2-methylpropanoate (ME-Br) initiator (50.0 mg, 0.178 mmol, prepared as in (25)) 
and 2,2’-bipyridine ligand (bpy) (55.8 mg, 0.358 mmol) were dissolved in 2 ml methanol and the 
solution deoxygenated with N2 for 30 minutes before being injected into the flask. The 
[MPC]:[ME-Br]:[CuBr]:[bpy] relative molar ratios were 25:1:1:2 respectively. The 
polymerization was conducted under a N2 atmosphere at 20°C. After 65 minutes a mixture of 
deoxygenated 2-(Diisopropylamino)ethyl methacrylate  (DPA) (2.67 g, 12.5 mmol; Scientific 
Polymer Products, USA) and methanol (3 ml) was injected into the flask, and after a further 48 h 
the reaction solution was diluted by adding 200 ml isopropanol and then passed through a silica 
column (Merk, Darmstadt, Germany) to remove spent Cu catalyst.  
 
Rhodamine (Rho)-PMPC30PDPA60 copolymer synthesis 
Rho-PMPC30-PDPA60 copolymer was synthesized by an ATRP procedure as previously 
described27. Briefly, a Schlenk flask was charged with MPC (1.20 g, 4.05 mmol). A rhodamine 
6G-based initiator prepared in-house (83.8 mg, 0.135 mmol) was dissolved in methanol (0.75 
ml) and added to the MPC. The solution was deoxygenated by bubbling N2 for 30 minutes after 
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which a mixture of CuBr (19.37 mg, 0.135 mmol) and bpy ligand (42.17 mg, 0.171 mmol) was 
added to the reaction mixture. The [MPC]:[Rho]:[CuBr]:[bpy] relative molar ratios were 
30:1:1:2 and the reaction was carried out under a N2 atmosphere at 20°C. After 40 min, a mixture 
of deoxygenated DPA (1.73 g, 8.10 mmol) and methanol (2 ml) was injected into the flask and 
48 h later the reaction solution was diluted with methanol (~70 ml) and opened to the 
atmosphere. When the suspension turned green, 200 ml chloroform was added to dissolve the 
copolymer and the solution passed through a silica column to remove the catalyst. After removal 
of the solvent, the solid was taken up into 3:1 chloroform:methanol and dialysed for 3 days 
against this solvent mixture to remove residual bpy ligand. After evaporation, the solid was 
dispersed in water, freeze-dried and dried in a vacuum oven at 80°C for 48 h.  
 
Preparation and characterisation of chemotherapeutic loaded polymersomes 
To produce polymersomes, 20 mg PMPC25-PDPA70 copolymer were dissolved in a 2:1 
chloroform:methanol solution and a co-polymer film formed by evaporating the solvent 
overnight in a vacuum oven at 50°C. The film was rehydrated using 2 ml of 100 mM PBS for 7 
days under continuous stirring.  This solution was sonicated for 15 minutes and then purified by 
gel permeation chromatography using a sepharose 4B size exclusion column to extract the 
fraction containing vesicles (~200 nm in diameter by dynamic light scattering analysis) and 
remove any remaining impurities. To generate rhodamine-labelled polymersomes rho-
PMPC30PDPA60 (5% v/v) was added to the PMPC25-PDPA70 prior to co-polymer film formation. 
To produce paclitaxel loaded polymersomes, 2 parts chloroform was mixed with 1 part methanol 
containing 500 µg paclitaxel prior to co-polymer film formation as described previously. The 
film was then rehydrated in 2 ml 100 mM PBS for 7 days under continuous stirring to produce 
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paclitaxel loaded polymersomes (250 µg/ml paclitaxel before purification; Table 1).  
Doxorubicin was encapsulated via a rehydration method as previously described28. Briefly, at the 
point of rehydration doxorubicin (final concentration 250 µg/ml) was added to the co-polymer 
film (either alone or paclitaxel loaded) in 2 ml of 100 mM PBS. The solution was then left for 7 
days under continuous stirring at room temperature before sonication (15 min) and purification 
via gel permeation chromatography. Polymersome size was determined by dynamic light 
scattering and encapsulated drug concentrations determined by high performance liquid 
chromatography (Table 1).     
 
Cell culture 
This study used the following HNSCC cell lines: Cal27 (ATCC, Manassas, VA, USA), CRL-
2095), FaDu (LGC Promochem, Middlesex, UK) and SCC4 (ECACC, Health Protection Agency 
Culture Collections, Salisbury, UK). Cal27 cells were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM), FaDu in RPMI-1640 both supplemented with 10% (v/v) fetal calf serum 
(FCS; BioSera, East Sussex, UK), 2 mM L-Glutamine, 100 IU/ml penicillin and 100 mg/ml 
streptomycin and SCC4 in DMEM and Ham’s F12 medium in a 1:1 (v/v) ratio supplemented 
with 10% (v/v) FCS, 2mM L-Glutamine, 100 IU/ml penicillin, 100 mg/ml streptomycin and 5 
mg/ml hydrocortisone.  
 
Normal oral keratinocytes (NOK) and fibroblasts (NOF) were isolated from biopsies obtained 
from the buccal and gingival oral mucosa from patients during routine dental procedures with 
written, informed consent (ethical approval number 09/H1308/66) as previously described29. 
Human dermal fibroblasts (HDF) were isolated from split thickness skin grafts obtained during 
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routine plastic surgery breast reduction and abdominoplasty operations, from fully consenting 
adults as previously described30. NOK were cultured in flavin and adenine enriched medium: 
DMEM and Ham’s F12 medium in a 3:1 (v/v) ratio supplemented with 10% (v/v) FCS, 0.1 mM 
cholera toxin, 10 ng/ml of epidermal growth factor (EGF), 0.4 mg/ml hydrocortisone, 0.18mM 
adenine, 5 mg/ml insulin, 5 mg/ml transferrin, 2 mM glutamine, 0.2 mM triiodothyronine, 0.625 
mg/ml amphotericin B, 100 IU/ml penicillin and 100 mg/ml streptomycin31. NOF and HDF were 
cultured in DMEM supplemented with 10% FCS, 2 mM glutamine, 100 IU ml penicillin and 100 
mg/ml streptomycin. All cells were incubated at 37°C in 5% CO2 and sub-cultured after brief 
treatment with trypsin-EDTA. 
 
Multicellular spheroid formation 
MCTS were generated from FaDu cells using the liquid overlay method as previously 
described29. Briefly, 100 ml of FaDu cells (12x104 per ml) were added to each well of a 96-well 
plate previously coated with 1.5% type V agarose (w/v in RPMI) and cultured for 4 days before 
being used for experiments. 
 
Internalization kinetic analysis using flow cytometry  
FaDu monolayers (3x105 per well) or MCTS were incubated with 300 μl or 100 μl of rho-
labelled PMPC-PDPA polymersomes diluted in medium (1 mg/ml), respectively, and incubated 
at 37°C for increasing lengths of time. At each time point the media was removed and the cells 
washed 3 times with PBS, trypsinised and resuspended in 4% paraformaldehyde. Fixed cells 
were analysed using a FACSArray analyser (BD Biosciences) (excitation 532 nm, emission 564-
606 nm) and the percentage of cells with fluorescence above control cells (cultured in media 
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alone) and median fluorescence of whole cell population calculated. Expression of scavenger 
receptors was assessed by flow cytometry in viable FaDu and HDF. Cells were incubated with 
primary antibody targeting either SR-BI or CD36 scavenger receptors (10 µg/ml) for 30 min at 
4°C and then incubated with a fluorescently-labelled secondary antibody under the same 
conditions. Fluorescent microscope images of cell monolayers were captured using an Axon 
ImageXpress (Union City, CA) (excitation 560 nm and emission 607 nm). MCTS were frozen, 
sectioned, stained with DAPI and images captured using a Zeiss Axioplan 2 fluorescent 
microscope (Carl Zeiss Inc. Germany) with a Q-imaging Retiga 1300R camera (QI Imaging, 
Arizona, USA) and Image Pro Plus image software (Media Cybernetics, Inc., MD, USA). 
 
Evaluation of cytotoxicity  
Polymersomes loaded with paclitaxel, doxorubicin or dual loaded were incubated with FaDu 
monolayers or MCTS at increasing polymer concentrations (10, 50 and 100 µg/ml) and free drug 
equivalents. For short exposure experiments drug concentrations of 1 µg/ml were used for all 
groups. Cell metabolic activity was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) analysis. Briefly, cell monolayers or MCTS were incubated 
at 37°C for 1 h with 0.5 mg/ml MTT solution. Incorporated stain was eluted using 400 μl of 
acidified isopropanol and 100 μl transferred into a 96-well plate and the optical density measured 
spectrophotometrically at 570 nm, with a 630 nm correction reference. For MCTS, bright field 
images were captured at 24 and 96 h using a Zeiss Axiovert 200M light microscope (Carl Zeiss 
Inc., Germany), AxioCam MRm camera (Carl Zeiss Inc. Germany) and Axiovision Rel. 4.6 
software (Carl Zeiss Inc., Germany).  
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Polymersome uptake blocking studies 
FaDu, NOF or HDF (5x105) were seeded into a 24 well plates and allowed to attach overnight 
before incubation with fucoidan (0.5, 1 or 2 mg/ml) or polyinosinic acid (0.25, 0.1 or 0.05 
mg/ml) for 30 minutes. For antibody blocking, cells were incubated with either anti-SR-BI/II 
(abcam), anti-CD36 (abcam) or IgG (abcam) all at a final concentration of 40 µg/mL for 1 h. For 
dual blocking cells were incubated with 20 µg/ml of both anti-SR-B1 and anti-CD 36 for 1 h. 
Cells were washed and incubated with rho-labelled polymersomes (1 mg/ml) for 1 h before being 
washed 3 times in PBS, trypsinised and fixed with 4% paraformaldehyde. Analysis was 
performed using a FACSArray analyser (BD Biosciences) (excitation 532 nm, emission 564-606 
nm) and the percentage of cells with fluorescence above control cells (cultured in media alone) 
and median fluorescence of whole cell population calculated. 
 
Immunoblotting 
Cell pellets were washed twice with PBS and protein extracted using lysis buffer (Merck 
Millipore) containing Complete Mini Protease Inhibitor Cocktail (Roche; used according to 
manufacturer’s instructions) and Benzonase (used according to manufacturer’s instructions). 
Protein concentration was measured using BCA Protein Assay kit (ThermoScientific). Total 
protein extracts (40 µg) were separated by NuPAGE® 4-12% Bis-Tris Gels (Life Technologies) 
and transferred to nitrocellulose membrane using an iBlot gel transfer device (Life 
Technologies). Following blocking of non-specific protein binding in 5% (w/v) dried milk, 3% 
(w/v) BSA in Tris-buffered saline containing 0.5% (v/v) Tween 20, membranes were incubated 
with antibodies directed to anti-SR-BI (1:500, abcam) or anti-MSR (1:1000, abcam) and 
overnight at 4°C or β-actin (1:4000; Sigma-Aldrich) for 1 h at room temperature followed by 
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anti-mouse or anti-rabbit IgG horseradish peroxidase secondary antibody (1:2,000; Cell 
Signaling Technologies). All antibodies were diluted in 5% (w/v) dried milk, 3% (w/v) BSA in 
Tris-buffered saline containing 0.5% (v/v) Tween 20. Immunoreactive proteins were visualised 
using Pierce enhanced chemiluminescence (Thermo Scientific). Densitometry was performed 
using Quality One software (Bio-Rad). 
 
Statistical analysis 
Data are expressed as mean ± standard deviation and significant differences between groups 
examined using either the Student’s unpaired t-test or one way independent ANOVA, with 
differences considered significant if p<0.05. Differences were mainly compared between 
HNSCC and NOK cells as NOK cells are epithelial and the most biologically comparable to 
HNSCC cell lines.  
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Results and Discussion 
Cellular internalisation kinetics.  
The site of action for most drugs lies within the cell, meaning intracellular delivery is crucial for 
therapeutic effect. Previous studies have shown that polymersomes are rapidly internalised by 
several cancer cell types where they enter endosomes22, and so we aimed to determine if the 
internalisation rates of polymersomes into HNSCC cell lines was different to normal cells. Flow 
cytometric analysis showed that rhodamine-conjugated PMPC-PDPA polymersomes were 
internalised by all cell types examined but with considerably different kinetics depending on the 
cell type (Figure 1A). FaDu cells internalised the polymersomes very rapidly, with 70% of FaDu 
cells containing detectable levels of polymersomes after just 2 minutes exposure. Other HNSCC 
cell lines, Cal27 and SCC4, also showed rapid uptake with at least 70% of the population 
containing polymersomes after 10 minutes exposure. Compared to the HNSCC cell lines, the 
normal oral cells showed significantly slower (p<0.05) internalisation rates at all time points 
between 5 and 60 minutes. The rates of internalisation were similar after 180 minutes incubation. 
Normal oral keratinocytes (NOK) internalised polymersomes slightly faster than normal oral 
fibroblasts (NOF) and human dermal fibroblasts (HDF) but by 60 minutes approximately 70% of 
all three of the normal cell populations contained polymersomes. All the cell types tested showed 
over 90% of cells contained polymersomes after 180 minutes. 
Faster internalisation into cancer cells compared to healthy cells is a highly desirable property 
when designing anti-cancer delivery systems as this may reduce adverse off-target effects.  Our 
internalisation data indicates that polymersomes may be preferentially targeting cancer cells over 
normal cells.  
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In addition to the rate of uptake, it is also important to determine the relative amount of 
polymersomes being delivered to each cell type over time to give a clue as to the possible doses 
achievable using polymersome drug delivery. To analyse drug delivery the amount of 
rhodamine-conjugated polymersomes taken up by each cell type over time was measured and 
compared to their equivalent unexposed control cells. For all cell types tested the fluorescence 
intensity increased over time and continued to increase for up to 24 hours (Figure 1B). At all-
time points examined between 5 and 480 minutes all three HNSCC cell lines contained 
significantly more polymersomes (p<0.01) when compared to the normal cells. The cells that 
internalised the most polymersomes per cell were the FaDu with the least polymersomes taken 
up by NOF (Figure 1B). Representative images of rhodamine-conjugated polymersomes 
internalised by FaDu cells demonstrate the increase in intensity over time (Figure 1C). These 
data show that HNSCC cells take up and accumulate polymersomes more rapidly than normal 
oral cells. The polymersomes tested here have an inherent ability to dissociate once they reach 
the low pH of the endosomal compartment, enabling fast release of their cargo into the cytosol 
after internalisation (Figure S1)19. This is in comparison to other delivery systems which exhibit 
good properties in the circulation but have difficulty releasing the cargo once internalised into 
target cells32.  
 
Class B Scavenger receptors mediate polymersome uptake in HNSCC cells and oral 
fibroblasts. To explain the increased uptake of polymersomes in cancer cells compared to normal 
cells we investigated the uptake mechanism. Previous studies in our laboratory have 
demonstrated that polymersomes are internalised via receptor-mediated endocytosis but the 
specific receptor/receptors have yet to be elucidated19.  Recently, other groups have reported an 
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association between nanoparticle uptake and scavenger receptor expression33, and recently a 
connection has been made between the differential expression of scavenger receptor type BI 
(SR-BI) between normal and cancerous cells34. Immunoblotting and densitometry were used to 
confirm the presence and relative expression of scavenger receptors in the different cell types 
and to determine if a different expression pattern was observed between normal oral and HNSCC 
cells. Expression of cell surface SR-BI (also known as CLA-1 (CD36 and LIMPII Analogous 1)) 
was higher in the HNSCC cell lines compared to the three normal cell types studied (Figure 2A-
B). In addition, NOF had significantly lower expression of SR-BI compared to NOK. Expression 
of the class A receptor, MSR-1, was not observed in either normal or cancerous cells (data not 
shown).  
The differences in the role of type B scavenger receptors in PMPC-PDPA binding and uptake 
between FaDu and fibroblasts could be a consequence of different expression patterns of these 
receptors on both cell types. In order to investigate this possibility we studied in detail, the cell 
surface expression of the type B receptors SR-BI and CD36 by FaDu and normal HDF cells 
using flow cytometry. Results in Figure 2C show the marked difference in scavenger receptor 
type B expression between these two cell types. FaDu cells express abundant cell surface SR-BI 
but only low levels of CD36, whereas HDF expressed low levels of SR-BI but high levels of 
CD36 (Figure 2C). Moreover, almost 100% of FaDu cells expressed SR-BI whilst the value for 
HDF was just 16%. In contrast, approximately 40% of FaDu cells expressed detectable levels of 
CD36 compared to almost 100% by HDF (Figure 2D). Therefore, FaDu cells express 
substantially more cell surface SR-BI than HDF.  These results could explain the reason for the 
rapid internalisation of polymersomes by HNSCC cells compared to primary epithelial cells and 
fibroblasts.  
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Scavenger receptors control the uptake of high and low density lipoproteins, extracellular RNA 
and DNA, and mediate the internalisation of hepatitis C virus35,35b. Uptake of nanoparticles by 
scavenger receptors has recently been shown by Saha et al (2012), where gold-coated 
nanoparticle uptake was inhibited using polyinosinic acid, a specific inhibitor of class A 
scavenger receptors33b. In addition, Patel et al (2010) showed that scavenger receptor types A 
and B specifically mediated uptake of oligonucleotide-coated gold nanoparticles by HeLa cells 
36. More importantly, the phosphorylcholine groups expressed by the PMPC chains bode well for 
high affinity interaction with class B receptors as both CD36 and SR-BI are involved in the 
uptake of phosphorylcholine bearing phospholipids16. To study the role of SR-BI and CD36 in 
the uptake of PMPC-PDPA polymersomes we pre-incubated FaDu and NOF with Fucoidan and 
polyinosinic acid (well-known ligands for scavenger receptors). Fucoidan is an anionic 
polysaccharide that targets both class A and B scavenger receptors while polyinosinic acid, a 
single stranded polynucleotide of inosine, specifically targets scavenger receptor type A37. 
Following pre-incubation with these ligands, cells were incubated with polymersomes without 
removing the ligands from the media. Results presented in figure 3A are striking, polymersome 
uptake is significantly inhibited in the presence of Fucoidan by FaDu cells (upper panel), and is 
almost abolished by NOF (lower panel), reaching fluorescent levels similar to untreated cells. 
Pre-incubation with polyinosinic acid did not affect polymersomes uptake by FaDu cells (Figure 
3B-upper panel). However, only the highest concentration of polyinosinic acid (0.25 mg/ml) 
produced a slight, although significant, decrease in polymersome uptake (p<0.05) by NOF 
(Figure 3B-lower panel).  These data suggest that type B scavenger receptors play a major role in 
polymersome uptake. So far three forms of type B scavenger receptors have been identified: 
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CD36, SR-BI and SR-BII, with the last two being splice variants of the same gene with each 
protein having the same extracellular loop but distinct cytoplasmic C-termini38. With the aim to 
differentiate which subtype of class B scavenger receptor is responsible for the binding of 
PMPC-PDPA polymersomes, we incubated FaDu and HDF with specific blocking antibodies 
against the extracellular loop of either CD36 or SR-BI/II and studied the effect of this on 
polymersome uptake. As shown in Figure 3C, blockade of SR-BI/II dramatically inhibited 
polymersome uptake in FaDu cells but failed to prevent internalisation by HDF. In contrast, 
blockade of CD36 alone did not inhibit polymersome internalisation in FaDu or HDFs. 
Interestingly, HDF continued to internalise polymersomes when one of the class B scavenger 
receptors was neutralised but uptake was significantly abolished when binding to both receptors 
was inhibited. This suggests that both SR-BI/II and CD36 work independently but 
simultaneously in PMPC-PDPA polymersome uptake. This data indicates that when one of the 
receptors is blocked the other can compensate for it or that the two receptors work 
synergistically. Even though at a first glance it seems that CD36 does not play a role in 
polymersome uptake in FaDu cells, it can be observed in Figure 3D that in order to produce the 
same degree of inhibition half of the concentration of neutralising IgG is needed when both SR-
BI/II and CD36 are blocked simultaneously compared to when only one receptor is inhibited (i.e. 
0.02 mg/mL of SR-BI/II and CD36 in combination generates approximately the same inhibition 
as 0.04 mg/mL of anti SR-BI/II alone). These data strongly indicate a role for class B scavenger 
receptors in mediating polymersome internalisation by HNSCC cells, in particular SR-BI. It is 
possible that the polymersome membrane structure is similar to that of a class B scavenger 
receptor ligands and this interaction drives endocytosis of polymersomes. Further detailed 
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experiments defining the interaction of polymersomes with class B scavenger receptors are 
currently underway in our laboratory in order to define this interaction at the molecular level.   
 
Characterisation of chemotherapeutically loaded polymersomes. Next we examined the 
efficiency of PMPC-PDPA polymersomes to encapsulate hydrophobic paclitaxel and hydrophilic 
doxorubicin, alone and in combination. Paclitaxel was encapsulated into PMPC-PDPA 
polymersomes by adding the drug to the polymer mixture in the organic phase prior to 
rehydration.  By contrast, doxorubicin was added during the rehydration stage of polymersome 
formation. In the case of dual loaded polymersomes, the paclitaxel was incorporated first 
followed by sequential loading of the doxorubicin during rehydration.  In all instances non-
encapsulated drug was removed from polymersome-encapsulated drug by gel permeation 
chromatography. High-performance liquid chromatography analysis revealed that the 
encapsulation efficiency for single and dual loaded drugs was between 37.1% ± 13.5% and 
49.1% ± 4.4%, demonstrating high reproducibility between polymer batches (Table 1). The 
loading capacity of paclitaxel into polymersomes was much higher than reported for liposomal 
preparations and can be attributed to the thicker hydrophobic bilayer in polymersomes39. Other 
groups have demonstrated both singular and dual loading of polymersomes with paclitaxel and 
doxorubicin using different polymers and methodologies for drug incorporation40,25,41. Chen et 
al, (2009) developed pH-sensitive PEG–PTMBPEC degradable polymersomes and demonstrated 
the controlled release of dual loaded paclitaxel and doxorubicin in a pH-dependent manner. In 
their studies drug release was significantly faster at mildly acidic pH compared to physiological 
pH41. Ahmed et al, (2006) reported that biodegradable polymersomes dual loaded with paclitaxel 
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and doxorubicin was able to permeate and reduce the volume of xenograft MDA-MB231 breast 
tumours in an in vivo model 25.  
Physiological analysis of the polymersomes by dynamic light scattering (DLS) and transmission 
electron microscopy (TEM), showed that like previous studies42 the polymersomes were 
spherical and had a Gaussian distribution with an average size of 208 ± 27.7 nm, 193.6 ± 7.8 nm, 
224.5 ± 43.5 nm for the paclitaxel, doxorubicin and dual loaded polymersomes respectively 
(Table 1). After storage at 4°C for 6 weeks the polymersomes remained spherical but their 
average size was slightly larger (but not significantly so; supplementary figure S2 and S3) when 
the same polymersomes were analysed by DLS and TEM. These data show that drug 
encapsulated polymersomes can be produced with highly reproducible size and stability that is 
not lost over a period of storage.   
 
Cytotoxicity of paclitaxel and doxorubicin loaded polymersomes to HNSCC cells in 2D 
culture. The ability of the polymersomes to deliver active drug was assessed in 2D monolayers 
of the HNSCC cell line FaDu (Figure 4) as this cell line was found to internalise polymersomes 
most rapidly. The cell response to paclitaxel, doxorubicin and dual loaded polymersomes as well 
as to empty polymersomes was assessed at 24 and 48 hours with increasing concentrations of 
drug and polymer respectively. Empty polymersomes were well tolerated at all concentrations 
and time points tested, confirming their biocompatibility as previously shown with other cell 
types20,27 (Figure 4).  After 24 hours, both free and polymersome-encapsulated drugs, either on 
their own or as combination therapy, killed FaDu cells in a dose-dependent manner (Figure 4). 
At 24 hours both paclitaxel (Figure 4A) and doxorubicin (Figure 4C) loaded polymersomes 
showed significantly (p<0.05) more killing compared to free drug alone at the two lower 
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polymer concentrations (10 and 50 µg/ml).  By contrast, at 24 hours, dual loaded polymersomes 
(Figure 4E) significantly reduced cell survival at all concentrations compared to the free drugs 
(p<0.05) and also when compared to polymersome-encapsulated paclitaxel or doxorubicin alone, 
showing that combined polymersome-delivered therapy is much better than single drug 
encapsulated therapy. The effect of combinational therapy, delivered via nanoparticles, has been 
extensively reviewed and current evidence shows that this combinational therapy is highly 
dependent on the molar ratios of drugs and the sequence in which they are delivered43.  In 
support of this, we observed that the cytotoxicity of dual loaded polymersomes is greater than 
polymersomes loaded with a single drug. Further studies to investigate the effect of varying drug 
ratios and use of different dosing schedules are now required. 
As anticipated, after 48 hours cell death was more pronounced than at 24 hours in all treated 
cells. However, no difference in cell survival was observed between FaDu cells treated with 
polymersome-encapsulated drugs and free drug except for the highest dose of dual loaded 
polymersomes, which significantly reduced cell viability (p<0.05) (Figure 4). Polymersome-
delivered chemotherapy killed HNSCC cells more compared to free drug after 24 hours, 
suggesting that polymersome-mediated drug delivery could show a significant improvement in 
treatment response.  However, this increased killing appears to be lost at 48 hours exposure and 
indicates that the benefit seen in polymersome-mediated therapy is due to the initial rapid uptake 
of the drug.  This advantage may be magnified in vivo where tumours are only exposed to drugs 
delivered via the circulation for a short period of time, making quick cellular uptake crucial for a 
drug’s success.  
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Cytotoxicity of single and combined drug-loaded polymersomes to FaDu monolayers after 
short exposure times. To determine if the rapid uptake kinetics of the polymersome-
encapsulated drugs was important for the improved cancer cell cytotoxicity over free drug, FaDu 
monolayers were incubated with drug-loaded polymersomes or free drug alone or in combination 
for up to 60 minutes. The drugs were then removed and cell viability measured after 24 and 96-
hour culture in drug-free medium.  After 24 hours the cell viability was reduced in an exposure 
time-dependent manner for both encapsulated and free drug treated cells. In addition, there was a 
significant overall reduction in the cell viability with the paclitaxel and dual loaded (Figure 
5A&E) polymersomes compared to their free drug equivalents at the 30 and 60 minute exposure 
times. Encapsulated doxorubicin displayed little cytotoxic advantage over free drug at these time 
points. Short exposure of polymersomes alone had no significant effect on cell survival after 24 
or 96 hours (Supplementary Figure S4). 
As expected the cytotoxic effect of all drugs was greatest after 96 hours culture post-exposure 
(Fig 5B, D and F). At this time point the killing achieved by encapsulated paclitaxel was nearly 
twice that achieved by free drug after only 10 minutes initial incubation (Figure 5B) and 
significantly more cancer cell killing was observed with encapsulated paclitaxel after 30 and 60 
minutes compared to free paclitaxel alone. Interestingly, encapsulated doxorubicin showed 
equivalent or less cytotoxicity than the free drug alone after 96 hours, suggesting that free 
doxorubicin is able to penetrate into the cell without the requirement of polymersomes (Figure 
5D). However, there is an increase in cell killing following short exposures for polymersome-
encapsulated combinational chemotherapy compared to free combined drug treatment (Figure 
5F). These data suggest that, after short exposure times, encapsulated paclitaxel is mainly 
responsible for cell cytotoxicity while encapsulated doxorubicin alone has little effect. However, 
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when these encapsulated drugs are combined enhanced killing is achieved. This may be because 
the cytotoxic action of paclitaxel is required for doxorubicin to exert its cytotoxic affects at short 
incubation times. It is possible that the action of paclitaxel on intracellular microtubule formation 
may disrupt the efflux of internalised doxorubicin thereby increasing its intracellular 
concentration and thus, cell cytotoxicity. Ahmed et al (2006) demonstrated that paclitaxel and 
doxorubicin loaded PEG-based polymersomes reduced the size of breast tumours grown 
subcutaneously in nude mice, demonstrating the clinical advantage of combination therapy25.  
 
Polymersome internalisation and cytotoxicity in a 3D model of HNSCC. MCTS are 3D cell 
culture models that possess a number of features similar to solid, expanding tumours in vivo. 
These features include a proliferative outer ring of cells, an inner hypoxic and necrotic core and a 
nutrient and pH gradient throughout the tissue which closely models naturally occurring 
tumours44. It is becoming widely accepted that testing drugs and delivery vehicles in MCTS is an 
essential step in drug development and improves the chances of selecting drugs which will be 
successful in vivo45. Here we used a FaDu MCTS model to study the diffusion of polymersomes 
into solid tumours and also the effects of drug-loaded polymersomes.  Firstly, we investigated by 
both flow cytometry and fluorescence microscopy whether rhodamine-conjugated polymersomes 
were able to penetrate into MCTS. The internalisation kinetics of polymersomes into cells 
cultured as a MCTS was much slower compared to cells cultured as monolayers. This is because 
the polymersomes have to travel through layers of tumour cells to gain access to ones that are 
deeper in the tumour mass and this takes longer than gaining entry into cells cultured as 
monolayers. After 24 hours 20% of the cells within the MCTS contained polymersomes and this 
increased overtime and by five days over 80% of the cells within the MCTS contained 
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polymersomes (Figure 6A). Figure 6B shows representative cross sections of the MCTS after 0, 
6, 24 and 120 hours. Polymersomes gradually penetrate into the MCTS from the surface and by 
five days are visible throughout the entire spheroid. These results are extremely promising as it is 
the central, hypoxic core of solid tumours that present the greatest challenge for treatment46. This 
is because drugs as well as oxygen can only diffuse approximately 200 µm into tissues and so the 
hypoxic centres of tumours are protected from the effects of chemotherapy. In fact, an increase 
in hypoxia in tumours is linked to poor prognosis in many cancers including HNSCC46. It is 
encouraging that these polymersomes, which are greater than 200 nm in diameter, were able to 
penetrate into the core of the MCTS as it has previously been found that nanoparticles greater 
than 100 nm diameter are impeded by the extracellular matrix and require enzymatic assistance 
to reach the core45. The most likely route by which the polymersomes reach the core of MCTS is 
by polymersome deformation. We have previously shown that the high level of entanglement in 
the hydrophobic membrane of PMPC-PDPA polymersomes enables polymersomes as large as 
400 nm in diameter to deform sufficiently to cross a 50 nm pore membrane. These 
polymersomes retain structural integrity and are able to retain their encapsulated load even after 
deformation47.  As polymersomes gain access to these central, hypoxic tumour areas they may 
rupture outside the cell because of the low pH of the tumour microenvironment at these sites. 
This in fact may be advantageous as hypoxic cells at these central tumour sites will be using 
anaerobic respiration and so will be unlikely to up-take polymersomes by endocytosis which is a 
highly energy-dependent process. Polymersomes and their load may also be delivered via the 
transcellular route via recurrent endocytosis and exocytosis; however this has yet to be 
investigated.  
25 
 
Drug-loaded polymersomes were then added to the MCTS and their effects on MCTS 
morphology and metabolic activity compared to empty polymersomes and free drug controls. 
Architecturally, after 24 hours the drug-encapsulated polymersome-treated MCTS retained 
structural integrity similar to that of the empty polymersome-treated controls, although the sizes 
of drug-treated MCTS were smaller than the controls (628 µm compared to 473 µm, 478 µm, 
537 µm for paclitaxel, doxorubicin and dual loaded, respectively). However, after 96 hours 
exposure to polymersome-encapsulated chemotherapy and free drugs the MCTS architecture was 
completely disrupted compared to controls due to loss of cell viability (Figure 6C).  Moreover, 
an MTT assay showed a trend towards better killing of MCTS with drug-loaded polymersomes 
compared to free drugs, however this did not reach statistical significance (Figure 6D). This 
demonstrates that after short exposure times the growth of the tumour is inhibited and with 
longer exposure the polymersomes and their encapsulated drugs are able to reach the central 
core, causing cytotoxicity throughout the MCTS. This is encouraging as the MCTS model 
provides a better representation of a naturally occurring tumour and demonstrates that these 
drug-loaded polymersomes are able to exert their cytotoxic effect to the central core of tumours.  
 
In conclusion, we have shown rapid uptake of pH-sensitive PMPC-PDPA polymersomes into 
HNSCC cells. Polymersomes were preferentially taken-up by cancer cells and this is likely to be 
due to their higher expression of scavenger receptors. Most importantly, we report for the first 
time the high affinity binding of a fully synthetic polymer with these receptors. We have also 
demonstrated the ability to encapsulate paclitaxel and doxorubicin in combination into 
polymersomes and have shown that polymersome mediated drug delivery increases the 
cytotoxicity compared to free drugs. The potential of superficially targeting tumour cells by 
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conjugating tumour-specific ligands to the surface of polymersomes48 may further decrease off-
target cytotoxicity and reduce the levels of drugs needed to achieve systemic coverage.  
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Table 1. Encapsulation efficiency and size of drug-containing polymersomes used in this study. 
Data is compiled from three independent batches and is expressed as mean ± SD.  
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Figure 1. Polymersome internalisation kinetics. Internalisation studies of polymersomes into 
three HNSCC cell lines (Cal 27, FaDu and SCC4) and three primary cells types (NOK, NOF and 
HDF). Rhodamine-labelled PMPC-PDPA polymersomes (1 mg/ml) were added to cell 
monolayers and incubated at 37°C for increasing lengths of time.  Cells were analysed using 
flow cytometry and the percentage of cells with fluorescence above control cells (A) and median 
fold increase in fluorescence of whole cell population calculated (B). Representative fluorescent 
microscopy images are shown for the polymersome uptake into FaDu cells (C). Scale = 100 µm. 
* denotes a statistically significant difference (One-way Independent ANOVA, p<0.05) of 
polymersome uptake into the different cancer cell lines compared to NOK. 
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Figure 2. Evidence for functional scavenger receptors in FaDu and NOF cells. Cell lysates 
from HNSCC (FaDu, Cal27 and SCC4) and primary cells (HDF, NOF and NOK) were separated 
by SDS-PAGE and immunoblotting performed for SR-BI and β-actin (as a loading control). A 
representative blot is shown for SR-BI (A) and the intensity of the band determined by 
densitometry and normalised to β-actin levels in the same sample (B). For SR-BI n=3 * denotes a 
statistically significant difference from corresponding NOK expression (One way independent 
ANOVA, p<0.05). 
(C) Expression of scavenger receptors assessed by flow cytometry in viable FaDu and HDF. 
Cells were first incubated with primary antibody targeting either SR-BI or CD36 scavenger 
receptors for 30 min at 4°C and then incubated with a fluorescently-labelled secondary antibody 
under the same conditions. (D) Percentage of fluorescent cells in each cell type normalised to 
control (wells treated just with secondary antibody). All experiments were performed in triplicate 
and each experiment was repeated independently three times. Data presented is representative of 
the three individual experiments. Error bars denote mean ± SEM. Statistical analysis: Student T-
test where *p<0.05, **p<0.01, ***p<0.001. 
 
 
 
 
 
 
 
 
32 
 
 
0 
50 
100 ***  
***  
***  
***  
^^^ 
^^^ 
C
 
0 0.05 0.1 0.25
M
e
d
ia
n
 f
lu
o
re
s
c
e
n
c
e
 i
n
te
n
s
it
y
 (
a
.u
.)
1
10
100
Untreated 
cells
0 0.5 1 2
M
e
d
ia
n
 f
lu
o
re
s
c
e
n
c
e
 
in
te
n
s
it
y
 (
a
.u
.)
1
10
100
Untreated 
cells
0 0.05 0.1 0.25
M
e
d
ia
n
 f
lu
o
re
s
c
e
n
c
e
 i
n
te
n
s
it
y
 (
a
.u
.)
1
10
100
1000
* *
Untreated 
cells
Untreated 
cells
0 0.5 1 2
M
e
d
ia
n
 f
lu
o
re
s
c
e
n
c
e
 i
n
te
n
s
it
y
 (
a
.u
.)
1
10
100
1000
*
*
****
* *
*
*
FE
%
 N
o
rm
. 
in
te
n
s
it
y
 r
a
ti
o
 
U
n
tr
e
a
te
d
 c
e
ll
s
Polyinosinic acid concentration (mg/ml)
Polyinosinic acid concentration (mg/ml)Fucoidan (mg/ml)
Fucoidan (mg/ml)
P
B
S
A
n
ti
 S
R
-B
I
A
n
ti
 C
D
3
6
A
n
ti
 S
R
-B
I
A
n
ti
C
D
3
6
C
o
n
tr
o
l 
Ig
G
Polymersomes
FaDu HDF 
0.00 0.01 0.02 0.03 0.04
0
50
100
%
 N
o
rm
. 
in
te
n
s
it
y
 r
a
ti
o
 
IgG concentration (mg/ml)
Control IgG
Anti-CD36
Anti-SR-BI
Anti-SR-BI + Anti-CD36
*** ***
***
^^^ 
***
^^^ 
^^^ 
^^^ 
D
A B
 
33 
 
Figure 3. Effect of scavenger receptors inhibition in polymersome uptake.  (A-B) FaDu and 
(C-D) NOF cells were pre-incubated for 1 h either with Fucoidan or polyinosinic acid. 
Rhodamine-labelled PMPC-PDPA polymersomes (1 mg/ml) were added afterwards to the wells 
and cells were incubated for another hour with polymersomes in the presence of the 
aforementioned ligands. Fluorescence intensities associated with the cells after the different 
treatments were measured by flow cytometry. (E) FaDu and HDF cells were pre-incubated for 1 
h with specific antiserum against either SR-BI/II, CD36, a cocktail of both antibodies, or IgG as 
a control. Rhodamine-labelled PMPC-PDPA polymersomes (1 mg/ml) were added to the wells 
and cells were incubated for 1 h with polymersomes in the presence of the blocking antiserum. 
Fluorescence intensities associated with the cells after the different treatments were measured by 
flow cytometry. F) Titration of anti-scavenger receptor type B antibody concentrations in FaDu 
cells. Cells were treated following the same protocol as in C). Data are shown for n=3 and are 
representative of three independent experiments. Error bars denote ± SEM. Statistical analysis: * 
symbolises statistically significant difference (One-way Anova, * p< 0.05, ** p<0.01, *** 
p<0.001) between untreated cells (negative control) and the different treated groups. ^ 
symbolises statistically significant difference (One-way Anova, ^ ^ ^ p<0.001) between cells 
incubated just with polymersomes (positive control) and groups pre-incubated with scavenger 
receptor ligands/antibodies. 
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Figure 4. Encapsulated drugs vs free drug cytotoxicity after 24 and 48 hours exposure. 
Paclitaxel (A-B), doxorubicin (C-D) or dual loaded polymersomes (E-F) were incubated with 
FaDu monolayers for either 24 (left panel) or 48 h (right panel) and compared to free drug or 
empty polymersome equivalents. An MTT assay was used to determine the percentage cell 
survival and the data normalised to empty polymersomes control. All experiments were 
performed in triplicate and each experiment was repeated independently three times. Data 
presented is representative of the three individual experiments.  * denotes a statistically 
significant difference from corresponding free drug equivalents (Student’s t-test, p <0.05) and ^ 
denotes a statistically significant difference from corresponding polymersome encapsulated drug 
(Student’s t-test, p <0.05). Error bars ± SD. 
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Figure 5. Encapsulated drugs vs free drug cytotoxicity after short exposure. Paclitaxel (A-B), 
doxorubicin (C-D) or dual loaded polymersomes (E-F) were incubated with FaDu monolayers 
for (10, 30, and 60 minutes) before additional culture for 24 (left panel) or 96 h (right panel) and 
compared to the same dose of free drug. An MTT assay was used to determine the percentage 
cell survival and the data normalised to empty polymersomes control. All experiments were 
performed in triplicate and each experiment was repeated independently three times. Data 
presented is representative of the three individual experiments. * denotes a statistically 
significant difference from the corresponding free drug equivalents (Student’s t-test, p <0.05). 
Error bars ± SD. 
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Figure 6. Diffusion of polymersomes into an in vitro 3D tumour model. Internalisation studies 
of empty and drug loaded polymersomes into FaDu MCTS. Rhodamine-labelled polymersomes 
(1 mg/ml) were incubated with MCTS for increasing length of time (24, 48, 96 and 120 h). 
MCTS were disaggregated and individual cells analysed using flow cytometry and the 
percentage of cells with fluorescence above control cells calculated (A). Representative 
fluorescent microscopy images are shown for 0, 6, 24 and 120 h time points. Scale bar= 100 µm 
(B). Light microscopy images reveal that drug loaded polymersomes (1 µg/ml) are able to 
disrupt normal tumour architecture after 96 hours. Scale bar= 500 µm (C). MTT assay showing 
percentage cell survival after treatment with either free or polymersome encapsulated drug (D). * 
p<0.05 tested using ANOVA and Bonferroni test for multiple comparisons. 
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